JP2022552371A5 - - Google Patents
Info
- Publication number
- JP2022552371A5 JP2022552371A5 JP2022522628A JP2022522628A JP2022552371A5 JP 2022552371 A5 JP2022552371 A5 JP 2022552371A5 JP 2022522628 A JP2022522628 A JP 2022522628A JP 2022522628 A JP2022522628 A JP 2022522628A JP 2022552371 A5 JP2022552371 A5 JP 2022552371A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- amino acid
- molecule
- sequence
- lnp
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962915304P | 2019-10-15 | 2019-10-15 | |
| US62/915,304 | 2019-10-15 | ||
| US202062959716P | 2020-01-10 | 2020-01-10 | |
| US62/959,716 | 2020-01-10 | ||
| US202063017040P | 2020-04-29 | 2020-04-29 | |
| US63/017,040 | 2020-04-29 | ||
| PCT/US2020/055844 WO2021076805A1 (en) | 2019-10-15 | 2020-10-15 | Mrnas encoding immune modulating polypeptides and uses thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022552371A JP2022552371A (ja) | 2022-12-15 |
| JP2022552371A5 true JP2022552371A5 (enExample) | 2023-10-24 |
Family
ID=73402111
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022522628A Pending JP2022552371A (ja) | 2019-10-15 | 2020-10-15 | 免疫調節ポリペプチドをコードするｍＲＮＡ及びその使用 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20240158458A1 (enExample) |
| EP (1) | EP4045527A1 (enExample) |
| JP (1) | JP2022552371A (enExample) |
| AU (1) | AU2020368447A1 (enExample) |
| CA (1) | CA3157859A1 (enExample) |
| WO (1) | WO2021076805A1 (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2021236855A1 (en) | 2020-05-19 | 2021-11-25 | Orna Therapeutics, Inc. | Circular rna compositions and methods |
| WO2022115645A1 (en) | 2020-11-25 | 2022-06-02 | Akagera Medicines, Inc. | Lipid nanoparticles for delivery of nucleic acids, and related methods of use |
| JP2024518546A (ja) * | 2021-05-12 | 2024-05-01 | ザ ブロード インスティテュート，インコーポレーテッド | 修飾されたｍＲＮＡ、修飾された非コードＲＮＡ、およびその使用 |
| JP7842232B2 (ja) * | 2022-02-18 | 2026-04-07 | 江蘇衆紅生物工程創薬研究院有限公司 | 生物活性分子の活性放出制御及び活性徐放を達成する方法及びその薬物への応用 |
| WO2023215498A2 (en) * | 2022-05-05 | 2023-11-09 | Modernatx, Inc. | Compositions and methods for cd28 antagonism |
| CA3256897A1 (en) | 2022-05-25 | 2023-11-30 | Akagera Medicines, Inc. | Lipid nanoparticles for the administration of nucleic acids and their methods of use |
| WO2024129826A2 (en) * | 2022-12-14 | 2024-06-20 | Grann Pharmaceuticals Inc. | Compositions and methods for modulating hsp70 activity |
| EP4680728A1 (en) * | 2023-03-17 | 2026-01-21 | Quell Therapeutics Limited | Treg therapy |
| WO2024240962A1 (en) * | 2023-05-25 | 2024-11-28 | Ethris Gmbh | Gm-csf-encoding nucleic acids, pharmaceutical compositions, methods and uses thereof |
| WO2025024674A2 (en) * | 2023-07-26 | 2025-01-30 | Promab Biotechnologies, Inc. | Method for treating local and distant tumors |
| WO2025264765A1 (en) * | 2024-06-18 | 2025-12-26 | Grann Pharmaceuticals Inc. | Compositions and methods for modulating heat shock protein 70 activity for treatment of inflammatory diseases |
| CN120041511B (zh) * | 2025-04-24 | 2025-09-02 | 浙江大学 | IL-4受体激活剂或M-CSF受体激活剂在增强mRNA编辑巨噬细胞效率中的应用 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8613481D0 (en) | 1986-06-04 | 1986-07-09 | Diatech Ltd | Translation of mrna |
| GB2284210B (en) | 1993-11-26 | 1997-11-12 | British Tech Group | Translational enhancer DNA from a kinesin gene |
| US5824497A (en) | 1995-02-10 | 1998-10-20 | Mcmaster University | High efficiency translation of mRNA molecules |
| AU2002364586A1 (en) * | 2001-12-21 | 2003-07-30 | Delta Biotechnology Limited | Albumin fusion proteins |
| WO2009061853A2 (en) * | 2007-11-05 | 2009-05-14 | Massachusetts Institute Of Technology | Mutant interleukin-2 (il-2) polypeptides |
| HUE060907T2 (hu) | 2014-06-25 | 2023-04-28 | Acuitas Therapeutics Inc | Új lipidek és lipid nanorészecske formulációk nukleinsavak bevitelére |
| CN108064176A (zh) * | 2015-04-22 | 2018-05-22 | 库瑞瓦格股份公司 | 用于治疗肿瘤疾病的含有rna的组合物 |
| AU2016341309A1 (en) * | 2015-10-22 | 2018-06-07 | Modernatx, Inc. | Cancer vaccines |
| JP7384512B2 (ja) * | 2015-10-22 | 2023-11-21 | モデルナティエックス インコーポレイテッド | 広域インフルエンザウイルスワクチン |
| HRP20230209T1 (hr) | 2015-10-28 | 2023-04-14 | Acuitas Therapeutics Inc. | Novi lipidi i lipidne formulacije nanočestica za isporuku nukleinskih kiselina |
| BR112019015797A2 (pt) * | 2017-02-01 | 2020-03-17 | Modernatx, Inc. | Composições de mrna terapêuticas imunomoduladoras que codificam peptídeos de mutação de oncogene de ativação |
| SG11202003965VA (en) | 2017-12-06 | 2020-06-29 | Pandion Therapeutics Inc | Il-2 muteins and uses thereof |
| WO2019144309A1 (en) * | 2018-01-24 | 2019-08-01 | Beijing Percans Oncology Co. Ltd. | Cytokine Fusion Proteins |
| US20190314291A1 (en) * | 2018-01-30 | 2019-10-17 | Modernatx, Inc. | Compositions and methods for delivery of agents to immune cells |
-
2020
- 2020-10-15 JP JP2022522628A patent/JP2022552371A/ja active Pending
- 2020-10-15 US US17/768,513 patent/US20240158458A1/en not_active Abandoned
- 2020-10-15 EP EP20807153.0A patent/EP4045527A1/en not_active Withdrawn
- 2020-10-15 WO PCT/US2020/055844 patent/WO2021076805A1/en not_active Ceased
- 2020-10-15 CA CA3157859A patent/CA3157859A1/en active Pending
- 2020-10-15 AU AU2020368447A patent/AU2020368447A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022552371A5 (enExample) | ||
| JP7778392B2 (ja) | 病的石灰化状態を治療するための組成物およびそれを使用する方法 | |
| JP4590033B2 (ja) | デュシェンヌ型筋ジストロフィー治療剤 | |
| US6727355B2 (en) | Pharmaceutical composition for treatment of Duchenne muscular dystrophy | |
| KR102939954B1 (ko) | 다논병 및 다른 자가포식 장애의 치료 방법 | |
| US12241079B2 (en) | Compositions and methods for hemoglobin production | |
| CN110325199A (zh) | 用于治疗苯丙酮尿症的基因疗法 | |
| JP2000325085A (ja) | デュシェンヌ型筋ジストロフィー治療剤 | |
| JP4836366B2 (ja) | デュシェンヌ型筋ジストロフィー治療剤 | |
| EP3991743A1 (en) | Immune inducer and pharmaceutical composition for preventing or treating aging-related diseases | |
| CN1993137A (zh) | 用于治疗心血管疾病的组合物和方法 | |
| JP2025534332A (ja) | 治療用核酸及びその使用方法 | |
| JP7380670B2 (ja) | Ｉｇｆ－１－暗号化ｄｎａ作製物及びｈｇｆ－暗号化ｄｎａ作製物を用いた神経病症治療 | |
| JP2017503022A (ja) | インビボで細胞に活性型テロメラーゼを提供する組成物および方法 | |
| KR20230150836A (ko) | 파브리병 치료를 위한 조성물 및 방법 | |
| JP5701747B2 (ja) | アルツハイマー病に対するｄｎａワクチン | |
| JP2022552378A5 (enExample) | ||
| JP2006500933A (ja) | プレｍＲＮＡのスプライシングを修飾するための方法および組成物 | |
| KR20230066453A (ko) | 비바이러스성 dna 벡터 및 fviii 치료제 발현을 위한 이의 용도 | |
| CN112654706B (zh) | 靶向淋巴细胞活化基因3(lag-3)的核酸适体及其用途 | |
| US20250297249A1 (en) | Antisense oligonucleotide complex | |
| WO2024186688A2 (en) | Compositions and methods for delivery of low dose effector agents | |
| CN121064280A (zh) | 一种抗肝癌hla-a*02型疫苗及其制备方法和应用 | |
| WO2024221049A1 (en) | Agents and method of treatment for optic conditions | |
| BR112017024141B1 (pt) | Composto compreendendo um polipeptídeo solúvel de ectonucleotídeo pirofosfato/fosfodiesterase-1 (enpp1), e seu uso |